Group 1: Financial Performance and Projections - The company expects the highest revenue contribution in Q4, with approximately two-thirds of the revenue coming from contracts signed in previous quarters [3] - The loss in the first three quarters is attributed to delayed revenue recognition due to the pandemic and significant R&D investments [3] - The company has a reasonable budget completion progress for the year [3] Group 2: Impact of Subsidized Loans - The implementation of subsidized loans is expected to accelerate existing demand from universities, with new budget requirements likely to be released by the end of the year [3] - Approximately 10% of the company's scientific instrument sales are expected to come from universities [4] - The demand for instruments from key universities (211 and 985) is anticipated to be more specialized, while provincial universities will have broader procurement needs [4] Group 3: Competitive Landscape - The policy encourages the purchase of domestic brands, but decisions remain with the universities based on their research needs and preferences [4] - The company aims to enhance its product variety and quality to better match market demands and gain recognition [4] Group 4: Market Outlook - The pandemic has caused delays in orders, but the impact on revenue recognition is more significant than on order volume [4] - The environmental instrument sector is expected to remain stable, with government investments continuing despite the pandemic [4] - The company plans to maintain competitiveness in the environmental sector through a diverse product and business platform [4] Group 5: Talent Acquisition and Management - The company recognizes the need for new talent in emerging sectors like education and healthcare, while existing staff will continue to manage their current domains [5] - The sales management model is similar across sectors, with a focus on product competitiveness and market coverage [5]

聚光科技（杭州）股份有限公司 2022 年第三季度报告 1 证券代码：300203 证券简称：聚光科技 公告编号：2022-073 聚光科技（杭州）股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 聚光科技（杭州）股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |------------------------------------------------------|-------------------|-------------------------|-- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥1,351,287,251.75, a decrease of 1.30% compared to the same period last year[26]. - The net loss attributable to shareholders was ¥86,272,409.97, representing a significant increase in loss of 704.50% year-on-year[26]. - Basic and diluted earnings per share were both -¥0.195, a decline of 712.50% from -¥0.024 in the same period last year[26]. - The company reported a total revenue of 1.35 billion yuan for the first half of 2022, a decrease of 1.30% compared to the same period last year[37]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was -119.9 million yuan, a decline of 32.90% year-on-year[37]. - The company's revenue for the reporting period was ¥1,351,287,251.75, a decrease of 1.30% compared to ¥1,369,110,976.34 in the same period last year[85]. - The company achieved a revenue of ¥1,283,680,029.99 from its main business, with a year-on-year decrease of 2.19%[88]. - The company's foreign revenue increased by 35.90% to ¥33,158,949.77, while domestic revenue decreased by 1.98% to ¥1,318,128,301.98[88]. Cash Flow and Investments - The net cash flow from operating activities improved by 20.14%, amounting to -¥366,950,521.24 compared to -¥459,499,250.36 in the previous year[26]. - The total investment amount for the reporting period was ¥66,048,219.47, a decrease of 87.38% compared to ¥523,338,542.00 in the same period last year[95]. - The company completed a financing round of 185 million yuan in July 2022, aimed at promoting the future business development of its subsidiary, Pujuy Medical[73]. - The company's R&D investment increased by 36.98% to ¥307,286,489.34, up from ¥224,326,701.03 in the previous year, primarily due to an increase in R&D personnel salaries[86]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,391,320,990.29, reflecting a 0.89% increase from the end of the previous year[26]. - The net assets attributable to shareholders decreased by 2.40% to ¥3,430,873,136.40 compared to ¥3,515,301,302.78 at the end of the previous year[26]. - The company's inventory increased by 2.29% to ¥1,608,993,570.10, compared to ¥1,358,215,089.00 at the end of the previous year[91]. - The company’s long-term borrowings rose by 1.03% to ¥2,489,094,921.58, compared to ¥2,361,105,631.65 at the end of the previous year[91]. Research and Development - The company has invested a total of 2.8 billion yuan in research and development, focusing on high-end analytical instruments and related consumables[35]. - The company has a research and development team of over 1,400 people and holds 633 authorized patents, including 225 invention patents[82]. - The company has implemented a stock incentive plan for new business units to ensure rapid growth in core instrument businesses[37]. - The company is focusing on developing new products and expanding applications in high-end analytical instruments, life sciences instruments, and industrial analysis instruments[37]. Market and Product Development - The company is focusing on expanding its market presence and enhancing its product offerings through new technologies[6]. - The total amount of new contracts signed during the reporting period was approximately 1.7 billion yuan, representing a growth of about 12% compared to the previous year[37]. - The new contracts signed by Puyue Technology amounted to approximately 600 million yuan, an increase of about 53% year-on-year, becoming a significant growth point for the company[37]. - The company is actively developing new technologies and products to enhance its market position in environmental monitoring and industrial process analysis[50]. Risks and Challenges - The company faces various risks including technological, market, and operational risks, which are detailed in the report[6]. - The company faces technology risks due to the competitive nature of the instrument and meter industry, emphasizing the need for continuous innovation to maintain its competitive advantage[103]. - The company faces significant market risks due to reliance on government and large enterprise clients, with demand heavily influenced by government policies and industry cycles[105]. - The company is at risk of talent loss due to high demand for experienced management personnel in a booming industry, which could hinder future growth[105]. Corporate Governance and Compliance - The company has maintained compliance with laws and regulations, ensuring transparency and protecting the rights of shareholders, especially minority shareholders[120]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[124]. - The company did not engage in any significant related party transactions during the reporting period[130]. - The semi-annual financial report has not been audited[126]. Future Outlook - The company aims to provide scientific decision-making support for environmental management through advanced data application and analysis techniques[42]. - The company has outlined a future outlook with a revenue growth target of 15% for the next fiscal year, driven by new product launches and market penetration[151]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 5,000 million earmarked for this purpose[154].

聚光科技（杭州）股份有限公司 2022 年第一季度报告全文 1 证券代码：300203 证券简称：聚光科技 公告编号：2022-031 聚光科技（杭州）股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|-------------------|---------------------------| | | 本报告期 ...

Financial Performance - The company's operating revenue for the reporting period was 3.75 billion RMB, a decrease of 8.55% compared to the same period last year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -350 million RMB, a decline of 522.04% year-on-year[6]. - The gross profit decreased by 300 million RMB compared to the same period last year due to declining revenue and rising operating costs[6]. - The company's total revenue for 2021 was approximately 3.75 billion yuan, a decrease of 8.55% compared to 2020[115]. - The net profit attributable to shareholders was -350 million yuan, representing a decline of 522.04% year-on-year[115]. - The main business revenue was 3.62 billion yuan, accounting for 96.65% of total revenue, with a year-on-year decrease of 9.24%[116]. - The revenue from instruments and related software and consumables was 2.09 billion yuan, which is 55.63% of total revenue, down 18.24% from the previous year[116]. - Domestic revenue was approximately 3.70 billion yuan, representing 98.63% of total revenue, with a decrease of 9.00% year-on-year[116]. - The company achieved a sales volume of 29,577 units in 2021, an increase of 12.85% compared to 2020[120]. Research and Development - The company increased its R&D investment by 72.38 million RMB compared to the previous year to maintain continuous innovation and technological leadership[6]. - The company has invested a total of 2.5 billion yuan in R&D, developing nearly 100 technology platforms across various fields, including spectroscopy, chromatography, and mass spectrometry[112]. - The total R&D investment amounted to ¥523,274,938.02, representing 13.95% of operating revenue, up from 11.20% the previous year[141]. - The number of R&D personnel increased by 25.06% to 1,487 from 1,189, with the proportion of R&D personnel rising to 22.38% from 19.63%[139]. - R&D expenses rose by 14.79% to ¥561,800,325.80 from ¥489,424,753.75, attributed to an increase in the total salary of R&D personnel[136]. Market and Business Strategy - The total amount of new contracts signed by the company was approximately 4.1 billion RMB, with a significant contribution of about 1.34 billion RMB from its subsidiary, which represents a growth of approximately 65% year-on-year[6]. - The company is focused on expanding its technology platforms and applications in various sectors, including semiconductor and environmental monitoring[43]. - The company aims to establish a comprehensive monitoring solution that integrates air quality, photochemical components, particulate matter, and toxic gases, contributing to the goal of building a beautiful China[49]. - The company is actively developing a range of online monitoring instruments for specific water quality factors, achieving laboratory-level analytical precision for low-concentration indicators in surface water[50]. - The company is expanding its market presence in the life sciences sector through the commercialization of new diagnostic systems and analytical instruments[136]. Risk Management - The company does not face major risks regarding its ongoing operations, and the industry does not exhibit overcapacity or continuous decline[6]. - The company is committed to addressing various risks, including technological, market, and operational risks, as detailed in the management discussion and analysis section[9]. - The company faces technology risks due to the rapid emergence of innovative companies and the need to continuously develop new products and technologies[165]. - The company is addressing operational risks related to environmental monitoring and data integrity, which could impact its reputation and operations[166]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with legal regulations[185]. - The company strictly adheres to information disclosure requirements, ensuring timely and fair access to information for all shareholders[181]. - The company has implemented a structured governance framework, including specialized committees to enhance decision-making capabilities[181]. - The company emphasizes compliance with laws and regulations, enhancing its compliance system in light of the issues identified in the Tangshan case[170]. Subsidiaries and Investments - The company established several new subsidiaries in 2021, including Hangzhou Shenghui Intelligent Technology Co., Ltd. with an investment of 3,500,000.00 CNY and a 65% ownership stake[128]. - The company disposed of 45% equity in Wuxi Zhongke, resulting in a loss of control with a fair value of 105,750,000.00 CNY and a gain of 53,789,449.75 CNY recognized[124]. - The company has established several business units, including Pujing Medical and Pukang Medical, focusing on clinical diagnostics and life sciences, leveraging advanced analytical technologies such as mass spectrometry and chromatography[99]. Environmental Commitment - The company is committed to supporting the national ecological civilization construction and pollution prevention efforts, enhancing environmental governance capabilities and promoting green high-quality development[57]. - The company is actively contributing to China's carbon peak and carbon neutrality goals, developing various carbon monitoring technologies and solutions to support greenhouse gas management[62]. - The company has created a comprehensive carbon monitoring solution that includes fixed pollution source monitoring, mobile monitoring, and satellite remote sensing, forming a three-dimensional network for urban greenhouse gas concentration monitoring[63].

Revenue and Profitability - Revenue for Q3 2021 was CNY 718,255,850.70, a decrease of 22.82% year-over-year[3] - Net profit attributable to shareholders was a loss of CNY 50,542,106.75, down 276.99% compared to the same period last year[3] - The company’s diluted earnings per share was -CNY 0.114, a decrease of 278.13% compared to the same period last year[3] - The net profit for the quarter was a loss of ¥62,111,252.96, contrasting with a profit of ¥78,977,680.64 in the same quarter last year[30] - The total comprehensive income attributable to the parent company was -62,645,733.48 CNY, compared to 42,933,790.85 CNY in the previous period[33] - Basic and diluted earnings per share were both -0.138 CNY, down from 0.095 CNY in the previous period[33] Cash Flow and Liquidity - Cash flow from operating activities showed a net outflow of CNY 422,759,085.30, a decline of 1210.73% year-over-year[9] - Cash inflow from operating activities totaled 2,204,608,934.99 CNY, a decrease of 14.6% from 2,579,636,153.40 CNY in the previous period[34] - Net cash outflow from operating activities was -422,759,085.30 CNY, compared to a net inflow of 38,061,369.25 CNY in the previous period[37] - Cash inflow from financing activities was 1,653,922,694.35 CNY, an increase of 12.3% from 1,472,060,990.57 CNY in the previous period[37] - Net cash flow from financing activities was 471,080,669.54 CNY, up from 245,125,705.61 CNY in the previous period[37] - The total cash and cash equivalents at the end of the period were 825,645,656.98 CNY, compared to 786,922,290.05 CNY at the end of the previous period[37] - The company reported a decrease in cash inflow from investment activities, totaling 16,411,747.45 CNY, down from 62,276,913.04 CNY in the previous period[37] Assets and Liabilities - Total assets increased to CNY 9,936,040,406.87, representing a growth of 6.03% from the end of the previous year[3] - The total liabilities increased to ¥5,860,995,393.50 from ¥5,182,126,186.57, indicating a rise in financial obligations[26] - The total equity attributable to shareholders decreased by 1.90% to CNY 3,694,337,212.11[3] - The total equity attributable to shareholders decreased to ¥3,694,337,212.11 from ¥3,765,888,263.87, reflecting a decline in shareholder value[26] - The company reported a significant increase in accounts receivable, totaling 1,465,125,379.86 CNY, compared to 1,412,228,032.21 CNY previously[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,483[10] - Zhejiang Ruiyang Technology Co., Ltd. holds 21.08% of shares, totaling 95,397,308 shares[10] - Zhejiang Pudu Technology Co., Ltd. holds 12.76% of shares, totaling 57,741,600 shares[10] - The largest shareholder, Zhejiang Ruiyang Technology Co., Ltd., has 1,410,000 shares frozen[10] - The second-largest shareholder, Zhejiang Pudu Technology Co., Ltd., has 46,078,600 shares pledged[10] - The company has not disclosed any related party relationships among other shareholders[13] Research and Development - Research and development expenses rose to CNY 411,296,121.51, an increase of 41.94% compared to the previous year[9] - Research and development expenses rose significantly to ¥411,296,121.51, compared to ¥289,772,007.72 in the previous year, indicating a focus on innovation[27] Operational Performance - Total operating revenue for the third quarter was ¥2,087,366,827.04, a decrease of 11.3% compared to ¥2,354,670,834.06 in the same period last year[27] - Total operating costs increased to ¥2,351,026,214.38, up from ¥2,334,436,342.07, reflecting a rise in operating expenses[27] - The company experienced a 67.15% increase in contract liabilities, totaling CNY 863,935,754.95, due to increased customer prepayments[6] - The company reported a significant increase in investment income, reaching CNY 61,465,415.09, up 1120.58% year-over-year[9] - The company’s inventory rose to 1,534,834,981.52 CNY, up from 1,175,608,845.09 CNY, reflecting an increase of about 30.5%[20] - The company sold a property in Beijing for 82,707,500 CNY, which is currently in the process of transaction[16] - The company plans to divest from certain PPP projects to optimize its asset-liability structure[16] - The company’s subsidiary, Puyutech, has launched multiple innovative products, contributing to significant sales growth in the high-end scientific instrument sector[16] Employee and Dividend Information - The company implemented a cash dividend policy, distributing a total of 8,858,148.00 CNY, with a dividend of 0.20 CNY per 10 shares based on a total share capital of 442,907,400 shares[16] - The company paid 904,651,109.33 CNY to employees, an increase from 742,149,184.51 CNY in the previous period[34] Legal and Compliance Issues - The company is facing potential risks due to legal issues involving employees, which may impact its operational services[16] Other Financial Information - The company has repurchased a total of 407,400 shares, accounting for 0.09% of the total share capital, with a total transaction amount of 4,876,346.88 RMB[14] - The maximum transaction price during the buyback was 12.00 RMB per share, and the minimum was 11.84 RMB per share[14] - The company plans to use repurchased shares for future employee stock ownership plans or equity incentive plans[14] - The report indicates that the company has not implemented any changes in restricted shares[14] - The company did not adjust the initial balance sheet items due to the new leasing standards implemented in 2021[40]

聚光科技（杭州）股份有限公司 2021 年半年度报告全文 聚光科技（杭州）股份有限公司 2021 年半年度报告 2021 年 08 月 1 聚光科技（杭州）股份有限公司 2021 年半年度报告全文 公司所处的仪器仪表行业属于技术密集型行业，公司产品或服务涉及多个 争优势和持续发展能力，甚至出现重大经营风险。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人丁建萍、主管会计工作负责人虞辉 及会计机构负责人(会计主 管人员)臧烁声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、技术风险 | --- | |----------------------------------------------------------------------| | | | 技术领域，不同产品间技术差异化明显，部分产品开发周期长。在鼓励创新、 | | 创业的政策影响下，国内各类创新、创业公司不断涌现，新技术、新应用、新 | | 模式大 ...

聚光科技（杭州）股份有限公司 2020 年年度报告全文 聚光科技（杭州）股份有限公司 2020 年年度报告 2021 年 04 月 1 聚光科技（杭州）股份有限公司 2020 年年度报告全文 公司所处的仪器仪表行业属于技术密集型行业，公司产品或服务涉及多个 争优势和持续发展能力，甚至出现重大经营风险。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人丁建萍、主管会计工作负责人虞辉及会计机构负责人(会计主管 人员)王锁梅声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、技术风险 | --- | |----------------------------------------------------------------------| | | | 技术领域，不同产品间技术差异化明显，部分产品开发周期长。在鼓励创新、 | | 创业的政策影响下，国内各类创新、创业公司不断涌现，新技术、新应用、新 | | 模式大量涌现，公 ...

聚光科技（杭州）股份有限公司 2020 年年度报告全文 聚光科技（杭州）股份有限公司 2020 年年度报告 2021 年 04 月 1 聚光科技（杭州）股份有限公司 2020 年年度报告全文 公司所处的仪器仪表行业属于技术密集型行业，公司产品或服务涉及多个 争优势和持续发展能力，甚至出现重大经营风险。 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人丁建萍、主管会计工作负责人虞辉及会计机构负责人(会计主管 人员)王锁梅声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、技术风险 | --- | |----------------------------------------------------------------------| | | | 技术领域，不同产品间技术差异化明显，部分产品开发周期长。在鼓励创新、 | | 创业的政策影响下，国内各类创新、创业公司不断涌现，新技术、新应用、新 | | 模式大量涌现，公 ...

聚光科技（杭州）股份有限公司 2021 年第一季度报告全文 聚光科技（杭州）股份有限公司 2021 年第一季度报告 2021 年 04 月 1 聚光科技（杭州）股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人丁建萍、主管会计工作负责人虞辉及会计机构负责人(会计主管 人员)王锁梅声明：保证季度报告中财务报表的真实、准确、完整。 2 聚光科技（杭州）股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 ...